2004N-0330 - Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee

  


  

  


  

  


  

  


  

  
FDA Comment Number : 
  

  
EC20
  



  

  

  



  

  
Submitter : 
  

  
Dr. David Healy
  

  
Date & Time: 
  

  
09/03/2004 06:09:45
  



  

  
Organization : 
  

  
Cardiff University
  



  

  
Health Professional
  


  

  
Category : 
  


  

  
Issue Areas/Comments 
  


  

  



  

  
GENERAL
  


  

  



  

  
GENERAL
  


  

  



  

  
 At some point in the past few weeks, Pfizer posted on the FDA website material purportedly relevant to the PDAC hearing on antidepressants in pediatric trials, scheduled for September 13th/14th.  This material contained a sustained ad hominem attack on me, much of which is manifestly false, raising questions as the motives for posting such material.  The material was apparently vetted before posting by FDA's chief counsel, Daniel Troy, who has formerly worked closely with Pfizer.  The attached documents offer a preliminary response.